Sandoz fails in Enbrel patent challenge, but Fed Circuit split
Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.
Glenmark becomes fifth generic to be charged with US antitrust violations
Glenmark Pharmaceuticals has been charged with conspiring to fix prices for generic drugs, according to a statement released by the US Department of Justice.
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.
Labrador drops BioFire suit after COVID-19 revelation
Labrador Diagnostics has dropped its controversial patent complaint against COVID-19 test developer BioMerieux.
J&J wants $25m over ‘contaminated’ fake medical tools
Johnson & Johnson has accused a medical supplier of distributing counterfeit surgical tools that are “bacterially contaminated and critically defective”.
LSPN Connect: MPP chief wants COVID-19 role
The executive director of the Medicines Patent Pool says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.
English appeals court refuses Neurim injunction for insomnia drug
The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.
Latham recruits two from Hogan Lovells
Latham & Watkins has added two life sciences-focused litigators, Arlene Chow and Ernest Yakob, to its New York office.
Gilead expands oncology business with Pionyr deal
Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.
Kymab victorious before UK Supreme Court in Regeneron appeal
The UK Supreme Court today has sided with biopharmaceutical company Kymab, allowing its appeal in a suit involving Regeneron and patents covering transgenic mice.
